Balaxi Pharmaceuticals Limited

Revenue growth of 40.3% on YoY basis, with operating EBITDA of Rs. 15.29 crore PAT stood at Rs. 8.23 crore Revenue from Pharmaceutical business grew by 40.4%…

Commissioning of the US-FDA, EU-GMP, WHO-Geneva Compliant Pharmaceutical Formulation facility is scheduled for March 2024 The unit will be equipped with cutting-edge technology that enables greater energy…